Anaerobutyricum soehngenii

About Caelus Health

Caelus Health is a private, pre-revenue biotech firm pioneering microbiome-based therapeutics. The company's core asset is a precision probiotic strain, Anaerobutyricum soehngenii, which has undergone multiple clinical studies for metabolic health and is positioned for an initial commercial launch as a supplement for prediabetes and type 2 diabetes. Founded by award-winning scientists with research dating back to 2012, Caelus aims to translate deep microbiome science into accessible, evidence-based health solutions, with a longer-term vision to address autoimmune diseases and cancers.

Therapeutic Areas